Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

被引：6
|
作者：
Siegel, David [1 ]
Weisel, Katja [2 ]
Zahlten-Kumeli, Anita
Medhekar, Rohan
Ding, Bifeng
Leleu, Xavier [3 ,4 ,5 ]
机构：
[1] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, 92 Second St, Hackensack, NJ 07601 USA
[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany
[3] Amgen Inc, Thousand Oaks, CA USA
[4] CHU Poitiers La Miletrie, Poitiers, France
[5] INSERM CIC 1402, Poitiers, France
来源：
LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 12期
关键词：
health-related quality of life; relapsed or refractory multiple myeloma; patient-reported outcomes; proteasome inhibitor; carfilzomib; Clinicaltrials; OPEN-LABEL; DEXAMETHASONE; CARFILZOMIB; LENALIDOMIDE; DARATUMUMAB;
D O I：
10.1080/10428194.2021.1941927
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved >= 10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.
引用
收藏
页码：3002 / 3010
页数：9
相关论文
共 50 条
  • [1] Health-related quality of life outcomes in relapsed and/or refractory multiple myeloma: a systematic review
    Sparano, Francesco
    Cavo, Michele
    Niscola, Pasquale
    Efficace, Fabio
    [J]. QUALITY OF LIFE RESEARCH, 2016, 25 : 123 - 124
  • [2] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Delforge, Michel
    Shah, Nina
    Miguel, Jesus San F.
    Braverman, Julia
    Dhanda, Devender S.
    Shi, Ling
    Guo, Shien
    Yu, Peiwen
    Liao, Weiqin
    Campbell, Timothy B.
    Munshi, Nikhil C.
    [J]. BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
  • [3] Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
    Kyriakou, Charalampia
    Murphy, Philip
    Petrucci, Maria Teresa
    Bacon, Pamela
    Lewis, Philip
    Gilet, Helene
    Arnould, Benoit
    Vande Broek, Isabelle
    Leleu, Xavier
    [J]. BLOOD, 2015, 126 (23)
  • [4] Patient Perspectives on Treatment Experience and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma
    Nathwani, Nitya
    Bell, Jill A.
    Cherepanov, Dasha
    Sowell, France Ginchereau
    Shah, Rachel
    McCarrier, Kelly
    Hari, Parameswaran
    [J]. BLOOD, 2020, 136
  • [5] COMPARISON OF PATIENTS' AND PHYSICIANS' PERCEPTIONS OF PATIENTS' BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Broek, I.
    Murphy, P.
    Petrucci, M.
    Kyriakou, C.
    Welslau, M.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Bottomley, A.
    Leleu, X.
    [J]. HAEMATOLOGICA, 2013, 98 : 443 - 443
  • [6] LONGITUDINAL COMPARISON OF PATIENTS' AND PHYSICIANS' PERCEPTIONS OF PATIENTS' HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Vande Broek, I.
    Petrucci, M. T.
    Leleu, X.
    Murphy, P.
    Welslau, M.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Kyriakou, C.
    [J]. HAEMATOLOGICA, 2014, 99 : 368 - 368
  • [7] EXPLORATION AND QUANTIFICATION OF THE DETERMINANTS OF BASELINE HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR PATIENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kyriakou, C.
    Petrucci, M.
    Welslau, M.
    Leleu, X.
    Vande Broek, I.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Murphy, P.
    [J]. HAEMATOLOGICA, 2013, 98 : 600 - 600
  • [8] Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
    Martin, Thomas, III
    Lin, Yi
    Agha, Mounzer
    Cohen, Adam D.
    Htut, Myo
    Stewart, A. Keith
    Hari, Parameswaran
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Z.
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Jackson, Carolyn C.
    Deraedt, William
    Gries, Katharine S.
    Fastenau, John
    Wu, Xiaoling
    Carrasco, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Jakubowiak, Andrzej
    Jagannath, Sundar
    [J]. BLOOD, 2020, 136
  • [9] Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
    Cella, David
    McKendrick, Jan
    Kudlac, Amber
    Palumbo, Antonio
    Oukessou, Abderrahim
    Vij, Ravi
    Zyczynski, Teresa
    Davis, Catherine
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (12) : 2455 - 2463
  • [10] Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
    David Cella
    Jan McKendrick
    Amber Kudlac
    Antonio Palumbo
    Abderrahim Oukessou
    Ravi Vij
    Teresa Zyczynski
    Catherine Davis
    [J]. Annals of Hematology, 2018, 97 : 2455 - 2463
12345